摘要
Commercial ureteral stents frequently encounter clinical issues, such as mucosal injury due to friction, bacterial colonization resulting in infections, and mineral encrustation compromising long-term use. To effectively address these challenges, we developed a bridge-like copolymer coating, namely, P(DMA-bMPC-bDMA) (PDMD), which was synthesized via reversible addition–fragmentation chain transfer polymerization. The PDMD architecture strategically positioned dopamine methacrylamide groups at both ends, generating a “molecular clamp” that provided robust dual-end self-adhesion and ensured uniform, stable anchoring to the polyurethane substrate. Compared to conventional single-end adhesive coatings, this “molecular clamp” approach significantly enhanced the integrity and durability under dynamic physiological conditions. In addition, the bridge-like structure also optimally introduced the central segment of 2-methacryloyloxyethyl phosphorylcholine, forming a highly effective hydration layer that dramatically reduced friction by 92% (coefficient of friction ∼ 0.032) and acted as a physical barrier to inhibit bacterial adhesion. Consequently, the PDMD-modified polyurethane samples inhibited the adhesion of common uropathogens such as Escherichia coli (>98.8%), Staphylococcus aureus (>92.2%), and Proteus mirabilis (>98.5%) and effectively prevented the formation of encrustation in dynamic in vitro and in vivo urinary tract infection models. Overall, this multifunctional surface treatment combining dual-end self-adhesion stability with both superlubrication and antifouling performances provides a substantial improvement over previous traditional coatings, enhancing biocompatibility, reducing complications, and markedly improving patient comfort and clinical outcomes for commercial ureteral stents.
危险品化学品经营许可证(带存储)